BCAB News and Press, BioAtla Inc. From 03/16/23

SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference c...

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that its President, Scott Smith, will...

Cancer-focused biotech BioAtla ( NASDAQ: BCAB ) announced Thursday that the FDA cleared its investigational new drug (IND) for BA3182, a bispecific antibody targeting advanced adenocarcinoma. Adenocarcinoma can develop in almost any area of the body, but the condition is most common i...

Following the IND clearance, the Company is advancing into a Phase 1 clinical study Potentially addressing most common subtypes of adenocarcinoma including colon, lung, breast, pancreas, and prostate SAN DIEGO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a ...

Oncology-focused biotech BioAtla, Inc. ( NASDAQ: BCAB ) lost ~47% to reach the lowest level in over five months after the company shared interim results from an ongoing Phase 2 study for its lead candidate BA3011 in patients with solid tumors. The trial is designed to evaluate the...

Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in PD-1 failure NSCLC continues to show strong antitumor activity in a highly refractory population with additional patients enrolled BA3011 Undifferentiated Pleomorphic Sarcoma (UPS) Phase 2 part 2 of the potentially registra...

Viatris Announces Appointments of Scott A. Smith and Elisha W. Finney to the Company's Board of Directors PR Newswire Directors Neil Dimick and Ian Read Retire PITTSBURGH , Dec. 29, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global he...

SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management ...

Gainers: NeuroSense Therapeutics NRSN +83%. Axsome Therapeutics (AXSM) +37%. Agile Therapeutics (AGRX) +31%. GreenLight Biosciences (GRNA) +26%. Femasys (FEMY) +11%. Losers: GeoVax Labs GOVX -14%. SIGA Technologies (SIGA) -14%. Eargo (EAR) -12%. BioAtla...

Gainers: Rent the Runway (RENT) +10%. BioAtla (BCAB) +9%. Adaptive Biotechnologies Corporation (ADPT) +5%. Accolade (ACCD) +5%. Nurix Therapeutics (NRIX) +5%. Losers: DocuSign (DOCU) -23%. Stitch Fix (SFIX) -16%. Comtech Telecommunications  (CMTL) -15%. View (VIEW) -12%. DBV Te...